Magnetic resonance spectroscopy to study hepatic metabolism in diffuse liver diseases, diabetes and cancer

World Journal of Gastroenterology

Volumn 16, Issue 13, 2010, Pages 1577-1586

  Dagnelie, Pieter C ^a   Leij Halfwerk, Susanne ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cancer; Cirrhosis; Diabetes; Diffuse liver disease; Hepatitis; Magnetic resonance spectroscopy

Indexed keywords

ANTIRETROVIRUS AGENT; ESTER; FRUCTOSE; GLYCEROPHOSPHOETHANOLAMINE; INTERFERON; NUCLEOSIDE TRIPHOSPHATE; PHOSPHATE; PHOSPHODIESTER; PHOSPHOETHANOLAMINE; PHOSPHOMONOESTER; PHOSPHORYLCHOLINE; RIBAVIRIN; UNCLASSIFIED DRUG;

ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; CHRONIC LIVER DISEASE; CONGENITAL DISORDER; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIFFUSE LIVER DISEASE; DISEASE SEVERITY; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM; FUNCTIONAL DISEASE; GLUCOSE METABOLISM; HEPATITIS A; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION; LIVER METABOLISM; MALIGNANT NEOPLASTIC DISEASE; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 77950867983     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i13.1577     Document Type: Review

References (56)

1. Cox IJ, Menon DK, Sargentoni J, Bryant DJ, Collins AG, Coutts GA, Iles RA, Bell JD, Benjamin IS, Gilbey S. Phosphorus-31 magnetic resonance spectroscopy of the human liver using chemical shift imaging techniques. J Hepatol 1992; 14: 265-275
2. Sijens PE, Van Dijk P, Dagnelie PC, Oudkerk M. Non-T1-weighted 31P chemical shift imaging of the human liver. Magn Reson Imaging 1995; 13: 621-628
3. Terrier F, Vock P, Cotting J, Ladebeck R, Reichen J, Hentschel D. Effect of intravenous fructose on the P-31 MR spectrum of the liver: dose response in healthy volunteers. Radiology 1989; 171: 557-563
4. Matson GB, Twieg DB, Karczmar GS, Lawry TJ, Gober JR, Valenza M, Boska MD, Weiner MW. Application of image-guided surface coil P-31 MR spectroscopy to human liver, heart, and kidney. Radiology 1988; 169: 541-547
5. van Wassenaer-van Hall HN, van der Grond J, van Hattum J, Kooijman C, Hoogenraad TU, Mali WP. 31P magnetic resonance spectroscopy of the liver: correlation with standardized serum, clinical, and histological changes in diffuse liver disease. Hepatology 1995; 21: 443-449
6. Sijens PE. Parametric exploration of the liver by magnetic resonance methods. Eur Radiol 2009; 19: 2594-2607
7. Cox IJ, Sharif A, Cobbold JF, Thomas HC, Taylor-Robinson SD. Current and future applications of in vitro magnetic resonance spectroscopy in hepatobiliary disease. World J Gastroenterol 2006; 12: 4773-4783
8. Klomp D, van Laarhoven H, Scheenen T, Kamm Y, Heerschap A. Quantitative 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver. NMR Biomed 2007; 20: 485-492
9. Lim AK, Patel N, Hamilton G, Hajnal JV, Goldin RD, Taylor-Robinson SD. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology 2003; 37: 788-794
10. Bell JD, Cox IJ, Sargentoni J, Peden CJ, Menon DK, Foster CS, Watanapa P, Iles RA, Urenjak J. A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver. Biochim Biophys Acta 1993; 1225: 71-77
11. Bailes DR, Bryant DJ, Bydder GM, Case HA, Collins AG, Cox IJ, Evans PR, Harman RR, Hall AS, Rose MR, Ross BD, Young IR. Localised phosphorus-31 NMR spectroscopy of normal and pathological human organs in vivo using phase encoding techniques. J Magn Reson 1987; 74: 158-170
12. Oberhaensli R, Rajagopalan B, Galloway GJ, Taylor DJ, Radda GK. Study of human liver disease with P-31 magnetic resonance spectroscopy. Gut 1990; 31: 463-467
13. Jalan R, Sargentoni J, Coutts GA, Bell JD, Rolles K, Burroughs AK, Taylor Robinson SD. Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models. Gut 1996; 39: 141-146
14. Taylor-Robinson SD, Sargentoni J, Bell JD, Saeed N, Changani KK, Davidson BR, Rolles K, Burroughs AK, Hodgson HJ, Foster CS, Cox IJ. In vivo and in vitro hepatic 31P magnetic resonance spectroscopy and electron microscopy of the cirrhotic liver. Liver 1997; 17: 198-209
15. Corbin IR, Ryner LN, Singh H, Minuk GY. Quantitative hepatic phosphorus-31 magnetic resonance spectroscopy in compensated and decompensated cirrhosis. Am J Physiol Gastrointest Liver Physiol 2004; 287: G379-G384
16. Dezortova M, Taimr P, Skoch A, Spicak J, Hajek M. Etiology and functional status of liver cirrhosis by 31P MR spectroscopy. World J Gastroenterol 2005; 11: 6926-6931
17. Noren B, Dahlqvist O, Lundberg P, Almer S, Kechagias S, Ekstedt M, Franzén L, Wirell S, Smedby O. Separation of advanced from mild fibrosis in diffuse liver disease using 31P magnetic resonance spectroscopy. Eur J Radiol 2008; 66: 313-320
18. Oberhaensli RD, Galloway GJ, Taylor DJ, Bore PJ, Radda GK. Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. Br J Radiol 1986; 59: 695-699
19. Boesch C, Elsing C, Wegmüller H, Felblinger J, Vock P, Reichen J. Effect of ethanol and fructose on liver metabolism: a dynamic 31Phosphorus magnetic resonance spectroscopy study in normal volunteers. Magn Reson Imaging 1997; 15: 1067-1077
20. Kachi K, Araki T, Uchiyama G. [Effect of intravenous fructose load on the P-31 MR spectrum of the cirrhotic liver] Nippon Igaku Hoshasen Gakkai Zasshi 1991; 51: 127-132
21. Dufour JF, Stoupis C, Lazeyras F, Vock P, Terrier F, Reichen J. Alterations in hepatic fructose metabolism in cirrhotic patients demonstrated by dynamic 31phosphorus spectroscopy. Hepatology 1992; 15: 835-842
22. Yamane Y, Umeda M, O'uchi T, Mitsushima T, Nakata K, Nagataki S. Phosphorus-31 nuclear magnetic resonance in vivo spectroscopy of human liver during hepatitis A virus infection. Dig Dis Sci 1994; 39: 33-38
23. Lim AK, Patel N, Hamilton G, Mylvahan K, Kuo YT, Goldin RD, Taylor-Robinson SD. 31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease. AJR Am J Roentgenol 2007; 189: 819-823
24. Cho SG, Kim MY, Kim HJ, Kim YS, Choi W, Shin SH, Hong KC, Kim YB, Lee JH, Suh CH. Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings. Radiology 2001; 221: 740-746
25. Tarasów E, Wiercińska-Drapało A, Jaroszewicz J, Siergiejczyk L, Orzechowska-Bobkiewicz A, Prokopowicz D, Walecki J. Metabolic disturbances in liver 1H MR spectroscopy in HIV and HCV co-infected patients as a potential marker of hepatocyte activation. Acta Radiol 2004; 45: 803-809
26. Orlacchio A, Bolacchi F, Angelico M, Mancini A, Cozzolino V, Cadioli M, Simonetti G. In vivo, high-field, 3-Tesla 1H MR spectroscopic assessment of liver fibrosis in HCV-correlated chronic liver disease. Radiol Med 2008; 113: 289-299
27. Menon DK, Harris M, Sargentoni J, Taylor-Robinson SD, Cox IJ, Morgan MY. In vivo hepatic 31P magnetic resonance spectroscopy in chronic alcohol abusers. Gastroenterology 1995; 108: 776-788
28. Dixon RM, Angus PW, Rajagopalan B, Radda GK. 31P magnetic resonance spectroscopy detects a functional abnormality in liver metabolism after acetaminophen poisoning. Hepatology 1992; 16: 943-948
29. Magee LA, Dixon RM, Kemp GJ, Redman CW, Styles P. 31P magnetic resonance spectroscopy of the liver in HELLP syndrome. Br J Obstet Gynaecol 1999; 106: 582-588
30. Hagspiel KD, von Weymarn C, McKinnon G, Haldemann R, Marincek B, von Schulthess GK. Effect of hypothyroidism on phosphorus metabolism in muscle and liver: in vivo P-31 MR spectroscopy study. J Magn Reson Imaging 1992; 2: 527-532
31. Roser W, Stock KW. 1H MRS of liver and brain in a patient with AL amyloidosis. Magn Reson Imaging 1997; 15: 993-996
32. Dixon RM, Ouwerkerk R, Rajagopalan B, Radda GK. 31P magnetic resonance spectroscopy of the liver in an infant with galactosaemia. MAGMA 1993; 1: 119-121
33. Oberhaensli RD, Rajagopalan B, Taylor DJ, Radda GK, Collins JE, Leonard JV, Schwarz H, Herschkowitz N. Study of hereditary fructose intolerance by use of 31P magnetic resonance spectroscopy. Lancet 1987; 2: 931-934
34. Seegmiller JE, Dixon RM, Kemp GJ, Angus PW, McAlindon TE, Dieppe P, Rajagopalan B, Radda GK. Fructose-induced aberration of metabolism in familial gout identified by 31P magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1990; 87: 8326-8330
35. Seegmiller JE, Dixon RM, Kemp GJ, Angus PW, McAlindon TE, Dieppe P, Rajagopalan B, Radda GK. An aberration of fructose metabolism in familial gout identified by 31P magnetic resonance spectroscopy of the liver. Trans Assoc Am Physicians 1990; 103: 298-306
36. Iles RA, Cox IJ, Bell JD, Dubowitz LM, Cowan F, Bryant DJ. 31P magnetic resonance spectroscopy of the human paediatric liver. NMR Biomed 1990; 3: 90-94
37. Cline GW, Rothman DL, Magnusson I, Katz LD, Shulman GI. 13C-nuclear magnetic resonance spectroscopy studies of hepatic glucose metabolism in normal subjects and subjects with insulin-dependent diabetes mellitus. J Clin Invest 1994; 94: 2369-2376
38. Hwang JH, Perseghin G, Rothman DL, Cline GW, Magnusson I, Petersen KF, Shulman GI. Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study. J Clin Invest 1995; 95: 783-787
39. Bischof MG, Krssak M, Krebs M, Bernroider E, Stingl H, Waldhäusl W, Roden M. Effects of short-term improvement of insulin treatment and glycemia on hepatic glycogen metabolism in type 1 diabetes. Diabetes 2001; 50: 392-398
40. Bischof MG, Bernroider E, Krssak M, Krebs M, Stingl H, Nowotny P, Yu C, Shulman GI, Waldhäusl W, Roden M. Hepatic glycogen metabolism in type 1 diabetes after long- term near normoglycemia. Diabetes 2002; 51: 49-54
41. Matyka K, Dixon RM, Mohn A, Rajagopalan B, Shmueli E, Styles P, Dunger DB. Daytime liver glycogen accumulation, measured by 13C magnetic resonance spectroscopy, in young children with Type 1 diabetes mellitus. Diabet Med 2001; 18: 659-662
42. Kishore P, Gabriely I, Cui MH, Di Vito J, Gajavelli S, Hwang JH, Shamoon H. Role of hepatic glycogen breakdown in defective counterregulation of hypoglycemia in intensively treated type 1 diabetes. Diabetes 2006; 55: 659-666
43. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 1992; 90: 1323-1327
44. Krssak M, Brehm A, Bernroider E, Anderwald C, Nowotny P, Dalla Man C, Cobelli C, Cline GW, Shulman GI, Waldhäusl W, Roden M. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 2004; 53: 3048-3056
45. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603-608
46. Dagnelie PC, Sijens PE, Kraus DJ, Planting AS, van Dijk P. Abnormal liver metabolism in cancer patients detected by (31)P MR spectroscopy. NMR Biomed 1999; 12: 535-544
47. Leij-Halfwerk S, Dagneli PC, Kappert P, Oudkerk M, Sijens PE. Decreased energy and phosphorylation status in the liver of lung cancer patients with weight loss. J Hepatol 2000; 32: 887-892
48. Leij-Halfwerk S, Dagnelie PC, van Den Berg JW, Wattimena JD, Hordijk-Luijk CH, Wilson JP. Weight loss and elevated gluconeogenesis from alanine in lung cancer patients. Am J Clin Nutr 2000; 71: 583-589
49. Leij-Halfwerk S, Dagnelie PC, Van Den Berg JW, Wilson JH, Sijens PE. Hepatic sugar phosphate levels reflect gluconeogenesis in lung cancer: simultaneous turnover measurements and 31P magnetic resonance spectroscopy in vivo. Clin Sci (Lond) 2000; 98: 167-174
50. Leij-Halfwerk S, van den Berg JW, Sijens PE, Wilson JH, Oudkerk M, Dagnelie PC. Altered hepatic gluconeogenesis during L-alanine infusion in weight-losing lung cancer patients as observed by phosphorus magnetic resonance spectroscopy and turnover measurements. Cancer Res 2000; 60: 618-623
51. Leij-Halfwerk S, Agteresch HJ, Sijens PE, Dagnelie PC. Adenosine triphosphate infusion increases liver energy status in advanced lung cancer patients: an in vivo 31P magnetic resonance spectroscopy study. Hepatology 2002; 35: 421-424
52. Stubbs M, Bhujwalla ZM, Tozer GM, Rodrigues LM, Maxwell RJ, Morgan R, Howe FA, Griffiths JR. An assessment of 31P MRS as a method of measuring pH in rat tumours. NMR Biomed 1992; 5: 351-359
53. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 1996; 56: 1194-1198
54. Raghunand N, Gillies RJ. pH and chemotherapy. Novartis Found Symp 2001; 240: 199-211; discussion 265-268
55. Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther 2006; 5: 1275-1279
56. Solga SF, Horska A, Hemker S, Crawford S, Diggs C, Diehl AM, Brancati FL, Clark JM. Hepatic fat and adenosine triphosphate measurement in overweight and obese adults using 1H and 31P magnetic resonance spectroscopy. Liver Int 2008; 28: 675-681